{
    "clinical_study": {
        "@rank": "40137", 
        "acronym": "NOCIFIM", 
        "arm_group": [
            {
                "arm_group_label": "ODM-104", 
                "arm_group_type": "Experimental", 
                "description": "Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral capsules given once daily for one day or three times daily for 7 days"
            }, 
            {
                "arm_group_label": "entacapone + levodopa/carbidopa", 
                "arm_group_type": "Active Comparator", 
                "description": "entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of escalating doses of\n      ODM-104 when given to healthy male volunteers."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The study is divided into two parts. Part one is a crossover study where healthy volunteers\n      will receive two doses of ODM-104 and one dose of placebo. Part II of the study is a\n      multiple ascending dose parallel group study where healthy volunteers will receive ODM-104\n      three times daily for seven days. Healthy volunteers taking part in Part II of the study\n      will also receive levo/carbidopa and entacapone four times daily on day 1 and levo/carbidopa\n      in addition to ODM-104 on day 9. The study will also look at the pharmacokinetic(how the\n      body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-104."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subjects aged between 18 and 45 years\n\n          -  BMI 18-30 kg/m2\n\n          -  Weight 55-95kg\n\n          -  Written informed consent\n\n          -  Good General Health\n\n        Exclusion Criteria:\n\n          -  Vulnerable subjects\n\n          -  Veins unsuitable for repeated venipuncture\n\n          -  Evidence of clinically significant cardiovascular, renal, hepatic, hematological, Gi,\n             pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disorder\n\n          -  History of or positive test for drug abuse\n\n          -  Any condition requiring regular concomitant medication\n\n          -  Blood donation or significant loss of blood within 2 months prior to screening\n\n          -  Abnormal 12 lead ECG finding of clinical relevance - HR <50bpm or >90bpm after 10\n             minutes in a supine position\n\n          -  Systolic blood pressure <90mmHg or >140mmHg after 10 minutes in a supine position\n\n          -  Diastolic blood pressure <50mmHg or >90mmHg after 10 minutes in a supine position\n\n          -  Abnormal 24 hour Holter recording of clinical relevance at screening\n\n          -  Any abnormal laboratory value, vital signs or physical examination causing a health\n             risk to the volunteer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840423", 
            "org_study_id": "3112001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ODM-104", 
                "description": "ODM-104", 
                "intervention_name": "ODM-104", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "entacapone + levodopa/carbidopa", 
                "description": "entacapone + levodopa/carbidopa", 
                "intervention_name": "Entacapone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "entacapone + levodopa/carbidopa", 
                "description": "entacapone + levodopa/carbidopa", 
                "intervention_name": "levodopa/carbidopa", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa", 
                "Entacapone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "First in man study", 
            "Volunteer study"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "contact": {
                "email": "rainard.fuhr@parexel.com", 
                "last_name": "Rainard Fuhr, MD", 
                "phone": "+ 49 30 30685 361"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Parexel International GmbH"
            }, 
            "investigator": {
                "last_name": "Rainard Fuhr, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.", 
        "overall_contact": {
            "email": "rainard.fuhr@parexel.com", 
            "last_name": "Rainard Fuhr, MD", 
            "phone": "+49 30 30685", 
            "phone_ext": "361"
        }, 
        "overall_contact_backup": {
            "email": "regina.boensch@parexel.com", 
            "last_name": "Regina Boensch, PhD", 
            "phone": "+49 30 30685", 
            "phone_ext": "5825"
        }, 
        "overall_official": [
            {
                "affiliation": "Parexel International GmbH", 
                "last_name": "Rainard Fuhr, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Orion Corporation, Orion Pharma", 
                "last_name": "angela ruck, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximal COMT inhibition and area under the COMT inhibition curve AUCC", 
            "measure": "Erythrocyte COMT inhibition.", 
            "safety_issue": "No", 
            "time_frame": "0, 0.16, 0.33, 0.5, 0.75,1.0,1.5, 2, 3, 4, 6, 10, 16, 24h post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "AUC under the plasma concentration curve", 
            "measure": "AUC", 
            "safety_issue": "No", 
            "time_frame": "0, 0.16, 0.33, 0.5, 0.75, 1, 1.5, 2, 2, 4, 6, 10, 16, 24h post dose"
        }, 
        "source": "Orion Corporation, Orion Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}